(2) Benefits to Other Interested Parties As discussed in the CY 2020 HPT final rule (84 FR 65538) and the CY 2026 OPPS/ASC proposed rule (90 FR 33856), we believe public access to hospital standard charge information can be useful to the public, including patients who need to obtain services from a hospital, consumers of healthcare who wish to view hospital standard charge information prior to selecting a hospital, employers and State governments searching for lower cost options for health care coverage, and other users of the MRF who may develop consumer-friendly price transparency tools or perform price analyses to uncover disparities or drive value-based policy development
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports
Implied FDA approval or review
This trial is part of a larger experiment that lasted from d 42 ante partum (ap) to d 128 post partum (pp)
COAs include purity results, identity confirmation data, analytical methods used, batch number, and test date
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
